A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months).

Trial Profile

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Fracture; Postmenopausal osteoporosis; Vertebral fracture
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM
  • Sponsors Amgen
  • Most Recent Events

    • 16 Apr 2018 Results (n=138) assessing effects of up to 10 years of denosumab on bone histology, bone remodeling, and bone matrix mineralization characteristics from Freedom and Freedom extension studies, published in the Journal of Clinical Endocrinology and Metabolism.
    • 08 Nov 2017 Results assessing nonvertebral fracture rates up to 10 years of Denosumab treatment (FREEDOM and FREEDOM extension), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 04 Apr 2017 Combined results of FREEDOM and FREEDOM- extension study (n=794) presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top